Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome

Rheumatology (United Kingdom)

Volumn 55, Issue 7, 2016, Pages 1325-1335

  Omenetti, Alessia ^a   Carta, Sonia ^b   Caorsi, Roberta ^c   Finetti, Martina ^a   Marotto, Daniela ^d   Lattanzi, Bianca ^e   Jorini, Mauro ^e   Delfino, Laura ^b   Penco, Federica ^c   Picco, Paolo ^c   Buoncompagni, Antonella ^c   Martini, Alberto ^a,c   Rubartelli, Anna ^b   Gattorno, Marco ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d ASL 2   (Italy)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

Anti IL 1 monoclonal antibody; IL 1; IL 1 receptor antagonist; NLRP3 inflammasome; PAPA syndrome; PSTPIP1

Indexed keywords

ACUTE PHASE PROTEIN; CANAKINUMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ALPHA; CRYOPYRIN; IMMUNOLOGIC FACTOR; INTERLEUKIN 1; NLRP3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MIDDLE AGED; MONOCYTE; PAPA SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROLINE SERINE THREONINE PHOSPHATASE INTERACTING PROTEIN 1GENE; SCHOOL CHILD; TREATMENT RESPONSE; YOUNG ADULT; ACNE VULGARIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, INFECTIOUS; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; DRUG EFFECTS; PATHOLOGY; PHYSIOLOGY; PYODERMA GANGRENOSUM; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTHRITIS, INFECTIOUS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-1; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PYODERMA GANGRENOSUM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84977103263     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew031     Document Type: Article

References (28)

1. Badour K, Zhang J, Shi F, et al. The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse. Immunity 2003;18:141-54.
2. Spencer S, Dowbenko D, Cheng J, et al. PSTPIP: a tyrosine phosphorylated cleavage furrow-associated protein that is a substrate for a PEST tyrosine phosphatase. J Cell Biol 1997;138:845-60.
3. Cote JF, Chung PL, Theberge JF, et al. PSTPIP is a substrate of PTP-PEST and serves as a scaffold guiding PTPPEST toward a specific dephosphorylation of WASP. J Biol Chem 2002;277:2973-86.
4. Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003;100:13501-6.
5. Smith EJ, Allantaz F, Bennett L, et al. Clinical, molecular, and genetic characteristics of PAPA Syndrome: a review. Curr Genomics 2010;11:519-27.
6. Cong F, Spencer S, Cote JF, et al. Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation. Mol Cell 2000;6:1413-23.
7. Rubartelli A, Cozzolino F, Talio M, Sitia R. A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J 1990;9:1503-10.
8. Andrei C, Dazzi C, Lotti L, et al. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell 1999;10:1463-75.
9. Varga G, Gattorno M, Foell D, Rubartelli A. Redox distress and genetic defects conspire in systemic autoinflammatory diseases. Nat Rev Rheumatol 2015;11:670-80.
10. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004;117:561-74.
11. Yu JW, Fernandes-Alnemri T, Datta P, et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 2007;28:214-27.
12. Demidowich AP, Freeman AF, Kuhns DB, et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 2012;64:2022-7.
13. Starnes TW, Bennin DA, Bing X, et al. The F-BAR protein PSTPIP1 controls extracellular matrix degradation and filopodia formation in macrophages. Blood 2014;123:2703-14.
14. Cortis E, de Benedetti F, Insalaco A, et al. Abnormal production of tumor necrosis factor (TNF)-alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. J Pediatr 2004;145:851-5.
15. Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 2005;22:262-5.
16. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 2005;44:406-8.
17. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009;161:1199-201.
18. Caorsi R, Federici S, Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012;12:81-6.
19. Caorsi R, Picco P, Buoncompagni A, Martini A, Gattorno M. Osteolytic lesion in PAPA syndrome responding to antiinterleukin treatment. J Rheumatol 2014;41:2333-4.
20. Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A. Increased NLRP3-dependent interleukin 1beta secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 2014;73:462-9.
21. Carta S, Tassi S, Delfino L, et al. Deficient production of IL- receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes. Ann Rheum Dis 2012;71:1577-81.
22. Tassi S, Carta S, Vene R, et al. Pathogen-induced interleukin-1beta processing and secretion is regulated by a biphasic redox response. J Immunol 2009;183:1456-62.
23. Tassi S, Carta S, Delfino L, et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc Natl Acad Sci U S A 2010;107:9789-94.
24. Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin- 1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007;56:3138-48.
25. Cortesio CL, Wernimont SA, Kastner DL, Cooper KM, Huttenlocher A. Impaired podosome formation and invasive migration of macrophages from patients with a PSTPIP1 mutation and PAPA syndrome. Arthritis Rheum 2010;62:2556-8.
26. Finetti M, Omenetti A, Caorsi R, et al. Failure of adalimumab treatment in three patients with PAPA syndrome. Ann Rheum Dis 2013;71:705.
27. Holzinger D, Austermann J, Lohse P, et al. A novel mutation in the PSTPIP1 gene is associated with an autoinflammatory disease distinct from classical pyogenic arthritis, pyoderma gangrenosum and acne syndrome. Arthritis Rheum 2011;63:S115.
28. Wang D, Hoing S, Patterson HC, et al. Inflammation in mice ectopically expressing human Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne (PAPA) Syndromeassociated PSTPIP1 A230T mutant proteins. J Biol Chem 2013;288:4594-601.